Volrustomig 启动方案探索性 II 期平台研究 (eVOLVE-01)
一项 II 期开放标签研究,旨在评估 Volrustomig 引发方案与其他抗癌药物联合治疗实体瘤受试者的安全性、耐受性、药代动力学、免疫原性和抗肿瘤活性 (eVOLVE-01)
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
研究概览
详细说明
This Phase II, platform, open-label, multicenter study will evaluate the efficacy, safety, and tolerability of volrustomig in combination with anticancer drugs in various solid tumor types.
This platform study currently includes 2 substudies:
Substudy 1: metastatic non-small cell lung cancer (mNSCLC) (non-squamous [NSQ]). Participants will be randomized in two treatment arms: Arm 1A and Arm 1B.
Substudy 2: mNSCLC (squamous [SQ] or NSQ). Participants will enroll to the Arm 2A only.
All arms will test a volrustomig dosing in combination with chemotherapy.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Beijing、中国、100730
- Research Site
-
Hangzhou、中国、310014
- Research Site
-
Jinan、中国、250013
- Research Site
-
Yantai、中国、264000
- Research Site
-
Zhengzhou、中国、450000
- Research Site
-
-
-
-
-
Batumi、乔治亚州、6010
- Research Site
-
Tbilisi、乔治亚州、0144
- Research Site
-
Tbilisi、乔治亚州、0112
- Research Site
-
Tbilisi、乔治亚州、'0159
- Research Site
-
Tbilisi、乔治亚州、186
- Research Site
-
Tbilisi、乔治亚州、0114
- Research Site
-
-
-
-
-
Changhua、台湾、50006
- Research Site
-
New Taipei City、台湾、23561
- Research Site
-
Taipei、台湾、106
- Research Site
-
Taipei、台湾、110
- Research Site
-
-
-
-
-
Belgrade、塞尔维亚、11000
- Research Site
-
-
-
-
-
Athens、希腊、115 27
- Research Site
-
Athens、希腊、12462
- Research Site
-
Elaiones、希腊、546 23
- Research Site
-
Piraeus、希腊、185 47
- Research Site
-
Thessaloniki、希腊、57001
- Research Site
-
-
-
-
-
Genoa、意大利、16132
- Research Site
-
Meldola、意大利、47014
- Research Site
-
Milan、意大利、20133
- Research Site
-
Naples、意大利、80131
- Research Site
-
Orbassano、意大利、10043
- Research Site
-
Perugia、意大利、06132
- Research Site
-
Rozzano、意大利、20089
- Research Site
-
Udine、意大利、33100
- Research Site
-
Verona、意大利、37134
- Research Site
-
-
-
-
-
Bois-Guillaume、法国、76031
- Research Site
-
Caen、法国、14076
- Research Site
-
Dijon、法国、21079
- Research Site
-
Montpellier、法国、34070
- Research Site
-
-
-
-
-
Geneva、瑞士、1205
- Research Site
-
Lausanne、瑞士、1011
- Research Site
-
Winterthur、瑞士、8401
- Research Site
-
Zurich、瑞士、8091
- Research Site
-
-
-
-
-
Cluj-Napoca、罗马尼亚、400641
- Research Site
-
Craiova、罗马尼亚、200542
- Research Site
-
Floreşti、罗马尼亚、407280
- Research Site
-
-
-
-
California
-
Los Angeles、California、美国、90067
- Research Site
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27514
- Research Site
-
-
-
-
-
Lisbon、葡萄牙、1649-035
- Research Site
-
Lisbon、葡萄牙、1169-050
- Research Site
-
Lisbon、葡萄牙、1400-038
- Research Site
-
Porto、葡萄牙、4099-001
- Research Site
-
-
-
-
-
A Coruña、西班牙、15009
- Research Site
-
Alcorcón、西班牙、28922
- Research Site
-
Barcelona、西班牙、08041
- Research Site
-
Madrid、西班牙、28041
- Research Site
-
Málaga、西班牙、29004
- Research Site
-
Pamplona、西班牙、31008
- Research Site
-
Santander、西班牙、39008
- Research Site
-
Santiago de Compostela、西班牙、15706
- Research Site
-
Valencia、西班牙、46026
- Research Site
-
Valencia、西班牙、46015
- Research Site
-
-
-
-
-
Seongnam、韩国、13620
- Research Site
-
Seoul、韩国、03722
- Research Site
-
Suwon、韩国、16247
- Research Site
-
-
-
-
-
Kuala Lumpur、马来西亚、59100
- Research Site
-
Kuching、马来西亚、93586
- Research Site
-
Perai、马来西亚、13700
- Research Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration.
- Life expectancy greater than or equal to (>=) 12 weeks.
- Adequate organ and bone marrow function.
- Body weight greater than (>) 35 kilograms (kg) at screening and at randomization.
- Histologically or cytologically documented NSQ NSCLC in substudy 1 and SQ or NSQ mNSCLC in substudy 2.
- Absence of sensitizing epidermal growth factor receptor (EGFR) mutations.
- Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L therapies.
- At least one measurable lesion not previously irradiated that can be accurately measured at baseline as >= 10 millimeter (mm) in the longest diameter.
Key Exclusion Criteria:
- Spinal cord compression.
- History of primary active immunodeficiency.
- Active or prior documented autoimmune or inflammatory disorders.
- Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant.
- Brain metastases unless asymptomatic, stable, and not requiring steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of radiation therapy and study enrollment.
- Prior chemotherapy or any other systemic therapy for Stage IV NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for local disease are eligible, provided that progression has occurred greater (>) 12 months from end of last therapy.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Substudy 1: Arm 1A: Volrustomig dose regimen 1 + Carboplatin and Pemetrexed
Volrustomig priming dose followed by volrustomig dosing regimen 1 in combination with carboplatin and pemetrexed. |
Participants will receive volrustomig via intravenous (IV) infusion.
其他名称:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. |
|
实验性的:Substudy 1: Arm 1B: Volrustomig dose regimen 2 + Carboplatin and Pemetrexed
Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with carboplatin and pemetrexed. |
Participants will receive volrustomig via intravenous (IV) infusion.
其他名称:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. |
|
实验性的:Substudy 2: Arm 2A: Volrustomig dose regimen 2 +Ramucirumab + Carboplatin + Pemetrexed or Paclitaxel
Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with ramucirumab and histology-specific chemotherapy (carboplatin+ either pemetrexed or paclitaxel). |
Participants will receive volrustomig via intravenous (IV) infusion.
其他名称:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. Participants will receive ramucirumab via IV infusion. Participants will receive paclitaxel via IV infusion. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间:From screening (Days -28 to Day -1) up to 2 year 10 months
|
The safety and tolerability of volrustomig in combination with other anticancer drugs in participants with specified solid tumors will be assessed. |
From screening (Days -28 to Day -1) up to 2 year 10 months
|
|
Confirmed Objective Response rate (ORR)
大体时间:Up to 2 year 10 months
|
ORR is defined as the percentage of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1). |
Up to 2 year 10 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Disease Control Rate (DCR)
大体时间:Up to 2 year 10 months
|
DCR is defined as the percentage of participants who have a CR or PR or who have stable disease (SD) after the date of randomization or first dose. |
Up to 2 year 10 months
|
|
Duration of Response (DOR)
大体时间:Up to 2 year 10 months
|
DOR is defined as the time from the date of first documented response until the date of documented progression or death due to any cause (in the absence of progression). |
Up to 2 year 10 months
|
|
Progression Free Survival (PFS)
大体时间:Up to 2 year 10 months
|
PFS is defined as the time from randomization or first dose until radiological progression or death due to any cause (in the absence of progression). |
Up to 2 year 10 months
|
|
Overall Survival (OS)
大体时间:Up to 2 year 10 months
|
OS is defined as the time from randomization or first dose until the date of death due to any cause. |
Up to 2 year 10 months
|
|
Serum Concentration of Volrustomig
大体时间:Up to 2 year 10 months
|
The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Trough concentration (Ctrough)
大体时间:Up to 2 year 10 months
|
The trough concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Maximum Observed Concentration (Cmax)
大体时间:Up to 2 year 10 months
|
The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Area Under the Curve (AUC)
大体时间:Up to 2 year 10 months
|
The AUC concentrations of volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Number of Participants with Positive Antidrug Antibodies (ADAs)
大体时间:Up to 2 year 10 months
|
The incidence of ADAs against volrustomig or other anticancer agents in serum will be assessed. |
Up to 2 year 10 months
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- D798KC00001
- 2023-509482-20-00 (注册表标识符:CTIS)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers can request access to anonymized individual patient-leveldata from AstraZeneca group of companies sponsored clinical trials via therequest portal Vivli.org. All requests will be evaluated as per the AZ disclosurecommitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes",indicates that AZ are accepting requests for IPD, but this does not mean allrequests will be approved.
IPD 共享时间框架
AstraZeneca will meet or exceed data availability as per the commitment smade to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共享访问标准
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure researchenvironmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.